These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 15202533)
1. ABCs of radioisotopes used for radioimmunotherapy: alpha- and beta-emitters. Waldmann T Leuk Lymphoma; 2003; 44 Suppl 3():S107-13. PubMed ID: 15202533 [TBL] [Abstract][Full Text] [Related]
2. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma. Marcus R Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024 [TBL] [Abstract][Full Text] [Related]
3. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122 [TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice. Hagenbeek A Leuk Lymphoma; 2003; 44 Suppl 4():S37-47. PubMed ID: 15154741 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma. Witzig TE Semin Oncol; 2003 Dec; 30(6 Suppl 17):11-6. PubMed ID: 14710398 [TBL] [Abstract][Full Text] [Related]
6. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016 [TBL] [Abstract][Full Text] [Related]
7. Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma. Multani P Int J Hematol; 2002 Dec; 76(5):401-10. PubMed ID: 12512834 [TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Wiseman GA; White CA; Witzig TE; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Grillo-López AJ Clin Cancer Res; 1999 Oct; 5(10 Suppl):3281s-3286s. PubMed ID: 10541376 [TBL] [Abstract][Full Text] [Related]
10. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300 [TBL] [Abstract][Full Text] [Related]
11. The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL). Bischof Delaloye A Leuk Lymphoma; 2003; 44 Suppl 4():S29-36. PubMed ID: 15154740 [TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma. Witzig TE Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S91-5. PubMed ID: 11587375 [TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan. Hendrix CS; de Leon C; Dillman RO Clin J Oncol Nurs; 2002; 6(3):144-8. PubMed ID: 11998607 [TBL] [Abstract][Full Text] [Related]
14. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma. Witzig TE Drugs Today (Barc); 2004 Feb; 40(2):111-9. PubMed ID: 15045033 [TBL] [Abstract][Full Text] [Related]
15. Current status of cancer therapy with radiolabeled monoclonal antibody. Oriuchi N; Higuchi T; Hanaoka H; Iida Y; Endo K Ann Nucl Med; 2005 Jul; 19(5):355-65. PubMed ID: 16164191 [TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac. Hartmann F; Horak EM; Garmestani K; Wu C; Brechbiel MW; Kozak RW; Tso J; Kosteiny SA; Gansow OA; Nelson DL Cancer Res; 1994 Aug; 54(16):4362-70. PubMed ID: 8044783 [TBL] [Abstract][Full Text] [Related]
17. The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma. Cheson BD BioDrugs; 2005; 19(5):309-22. PubMed ID: 16207072 [TBL] [Abstract][Full Text] [Related]
18. Rituxan immunotherapy and zevalin radioimmunotherapy in the treatment of non-Hodgkin's lymphoma. White CA Curr Pharm Biotechnol; 2003 Aug; 4(4):221-38. PubMed ID: 14529425 [TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy of relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Dillman RO Curr Hematol Rep; 2003 Jan; 2(1):30-7. PubMed ID: 12901152 [TBL] [Abstract][Full Text] [Related]
20. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Wiseman GA; White CA; Stabin M; Dunn WL; Erwin W; Dahlbom M; Raubitschek A; Karvelis K; Schultheiss T; Witzig TE; Belanger R; Spies S; Silverman DH; Berlfein JR; Ding E; Grillo-López AJ Eur J Nucl Med; 2000 Jul; 27(7):766-77. PubMed ID: 10952488 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]